Serial intravascular ultrasound analysis of edge recurrence after intracoronary gamma radiation treatment of native artery in-stent restenosis lesions

In the Washington Radiation for in-Stent restenosis Trial (WRIST), patients were first treated with conventional techniques and then randomized to eit her gamma -irradiation (Ir-192) or placebo (dummy seeds). In the Ir-192 gro up with native coronary in-stent restenosis, we identified 8 patients with edge recurrence and compared them with 21 patients with no recurrence. Seri al (postirradiation and follow-up) intravascular ultrasound analysis was pe rformed according to conventional methods. When compared with nonrecurring lesions, lesions with distal edge recurrence had (1) greater decrease in me an distal lumen cross-sectional area (-3.0 +/- 1.2 vs -0.7 +/- 1.0 mm(2), p = 0.0002), (2) no change in mean distal external elastic membrane cross-se ctional area versus an increase in mean distal cross-sectional area of 1.0 +/- 0.9 mm(2) in nonrecurring lesions (p = 0.0047), and (3) a greater incre ase in mean distal plaque + media cross-sectional area (2.9 +/- 1.2 mm vs 1 .7 +/- 0.6 mm(2), p = 0.0103). Within the stented segment, the nonrecurring lesions had no decrease in mean lumen and no increase in mean intimal hype rplasia cross-sectional area. Conversely, lesions with distal edge recurren ce had a significant decrease in mean intrastent lumen cross-sectional area (-1.7 +/- 1.7 mm(2)) and a significant increase in mean intrastent intimal hyperplasia cross-sectional area (1.6 +/- 1.6 mm(2)). Lesions with distal edge recurrence also had a greater decrease in mean proximal lumen cross-se ctional area (-1.7 +/- 1.3 vs -0.3 +/- 0.8 mm(2), p = 0.0213), with a trend toward a greater increase in mean proximal plaque + media cross-sectional area. Thus, edge recurrence after Ir-192 treatment of in-stent restenosis i s the result of neointimal hyperplasia (part of generalized treatment failu re) and the absence of radiation-induced positive remodeling. (C)2001 by Ex cerpta Medica, Inc.